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Background: Cerebrospinal fluid absorption (CSF) at the cribriform plate is mediated by direct extracranial
connections to the lymphatic system. Given the accessibility of these pharmacologically responsive vessels we
hypothesized that the rate of CSF outflow can be modulated via the intranasal delivery of drugs known to affect
lymphatic contractile activity.
Findings: Fluid was infused into the lateral ventricle of anesthetized sheep and inflow rate and CSF pressure measured
during intranasal administration of pharmacological agents. CSF absorption was calculated at steady-state CSF pressures.
The ability of a pharmacological agent to alter CSF absorption was related to the steady-state intracranial pressure (ICP),
the concentration and the class of pharmacological agent delivered. An increase in drug concentration correlated with
an increase in CSF absorption at high ICP (45 cm H2O, r = 0.42, p = 0.0058). Specifically, the delivery of NG-monomethyl
L-arginine (L-NMMA) significantly increased CSF absorption by 2.29 fold over no treatment (2.29 ± 0.34 mL/min),
while the thromboxane A2 analogue U46619 resulted in a 2.44 fold increase in CSF absorption over no treatment
(2.44 ± 0.55 mL/min). Saline delivery did not significantly increase CSF absorption (0.88 ± 0.097 mL/min). A trend of
increased CSF absorption upon noradrenaline delivery was observed: however, this did not reach statistical significance.
Increasing drug concentrations inversely correlated with CSF outflow resistance across all drug classes (r = −0.26,
p = 0.046).
Conclusions: The administration of nebulized pharmacological agents intranasally has the potential to provide an
alternate method to non-invasively modulate CSF absorption and outflow resistance.Introduction
The regulation of intracranial homeostasis is strictly
controlled due to the finite space offered by the fixed
volume of the skull. As defined by the Monroe-Kellie
hypothesis, tight volumetric regulation of the cerebro-
spinal fluid (CSF), blood and tissue spaces is critical
in maintaining fluid balance; deflections in any of these
volumes outside of the autoregulatory capacity of the
brain can result in cerebral edema, high intracranial
pressures, and compromised cerebral perfusion. The
primary mechanism to control intracranial pressure
(ICP) is via regulation of CSF production and absorp-
tion within the ventricular and subarachnoid spaces* Correspondence: hkim@sri.utoronto.ca
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unless otherwise stated.[1]. Strong evidence supports a mechanism where
the absorption of CSF occurs extracranially at the
cribriform plate via the ethmoid turbinate lymphatics
[2-4]. Indeed, a significant portion of CSF absorption
occurs through the foramina and directly into the ex-
tracranial lymphatics. Restriction of this pathway re-
sults in increased resistance, decreased outflow and raised
ICP [5-7].
Given the direct connection between the CSF com-
partment and the pharmacologically responsive lymphatic
vasculature within the turbinate region, the potential
exists to modulate lymphatic pumping and thus CSF
absorption. Potential drugs that have been found to modu-
late lymphatic contractile activity include noradrenaline
(NA). Indeed, NA binding at <10-6 M to α-adrenergic re-
ceptors can increase phasic contractions and increase flow
on quiescent vessels, however NA stimulation of vessels. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain





















































Figure 2 Intracranial pressure and CSF outflow relationships upon intra
examples of pressure/flow curves of (A) saline delivery, (B) noradrenaline (NA
(D) U46619 treated at 0.1 μM and 1.0 μM and (E) U46619 at 1 mM. (A to D) In
intranasal delivery, and (×) represents the second intranasal delivery. (E) No tre
Linear regression lines for each treatment are shown.
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reduced contraction force and outflow [8-12]. Similarly,
the binding of thromboxaneA2, or its analogue U46619 to
its’ receptors have been found to increase the synthesis of
inositol-triphosphate (Ins(1,4,5)P3) and augment smooth
muscle contractions in a concentration-dependent fashion;
higher concentrations lead to vessel spasm and attenuate
flow [13-17]. In contrast, the nitric oxide competitor NG-
monomethyl L-arginine (L-NMMA) inhibits lymphatic
contractions [18].
Utilizing these pharmacological agents, the aim of
these experiments was to test whether the intranasal de-
livery of these drugs can alter CSF absorption. We have
found that indeed this is the case and provide a proof-
of-concept for the possibility to influence CSF absorp-






























nasal delivery of pharmacological agents. Shown are representative
) at 50 μM and 500 μM, (C) L-NMMA treated at 10 μM and 100 μM and
each experiment (○) represents no treatment (NT), (□) represents the first















































Figure 3 CSF outflow correlated with drug concentration at
(A) 25 cmH2O and (B) 45 cmH2O ICP. In order to address whether
a correlation existed between CSF outflow and an overall drug effect,
data points from all agents tested at no drug treatment (NT), the
delivery of the first set of agents (Drug Conc.#1; 50 μM NA, 10 μM
L-NMMA, 0.1 μM U46619) and the delivery of the second set of
agents (Drug Conc.#2; 500 μM NA, 100 μM L-NMMA, 1 μM U46619)
were plotted against CSF outflow, which was calculated from linear
regression analysis derived from the raw data using steady-state
pressures of (A) 25 cmH2O and (B) by extrapolation at 45 cmH2O.
The straight line linking the averages within each treatment group
was calculated with the Pearson correlation test.




After at least 48 hours for acclimatization, sheep (15–
45 kg) were fasted 12 hours prior to surgery. All sheep
experiments were acute followed by euthanasia with
an IV injection of sodium pentobarbital into the cathe-
terized cephalic vein using a dose of 1 mL/5 kg of
Euthanyl Forte. Thirty-six animals were used in the
study with 22 included in subsequent data analysis; 14
were excluded due to surgical and/or technical issues.
Experiments were approved by the ethics committee at
Sunnybrook and Women’s College Health Sciences Centre
and conformed to the guidelines set by the Canadian
Council on Animal Care and the Animals for Research Act
of Ontario.
Surgical procedures
Sodium pentothal (15–25 mg/kg) was given intraven-
ously to induce anesthesia. Sheep were set in a ventral
position, intubated, ventilated and surgical anesthesia
was maintained with 2-3% Isoflurane/oxygen. An 18–
20 Ga catheter was placed in the cephalic vein for
venous pressure measurements. An IV line provided hy-
dration using lactated Ringers solution at 5 mL/kg/hr.
The opposite cephalic vein was connected to a fluid-
filled transducer to record venous pressure. Midsagittal
and coronal incisions were made in the scalp to expose
the coronal suture and the scalp and posterium pulled
aside. A hole was drilled in the skull lateral to the sagit-
tal suture and at approximately 10 degrees to the sagittal
plane. Two 18 or 20 Ga angiocatheters were inserted
through the hole into each lateral ventricle of the brain
and sealed in place.
Constant pressure experiments
Using a modified protocol described in [7], a reservoir
filled with lactated Ringers solution was connected to
one lateral ventricular catheter while a fluid-filled trans-
ducer to measure ICP was connected to the contralateral
ventricle by the second catheter. For pre-drug treatment
a stable baseline ICP was recorded indicating inflow was
equal to outflow, and then the reservoir was raised 5 cm.
A steady-state pressure was achieved within 5 minutes
and at this point the flow of lactated Ringers into the
ventricle was recorded for the next 5 minutes via a drop
counter. The reservoir was raised again 5 cm and the
procedure repeated. When complete, the reservoir was
lowered and ICP returned to baseline. Subsequently,
one application of a 20 mL volume (10 mL per nostril)
of either saline (n = 5) or drug was nebulized using a
NasoNeb nebulizer (MedInvent, LLC, White Bear Lake,
Mn, USA) and the above protocol was repeated. The
drugs used were noradrenaline at 50 μM and 500 μM(n = 5), L-NMMA (Santa Cruz Biotechnology, Santa
Cruz, USA) at 10 μM and 100 μM (n = 4) and U46619
(Santa Cruz Biotechnology) at 0.1 μM, 1 μM and 1 mM
(n = 8). CSF pressure was monitored using a data acqui-
sition system.
Data analysis
CSF absorption Using the linear equations derived from
each single experiment, we calculated theoretical CSF
outflow rates at preset intracranial pressures of 25 cmH2O
and 45 cmH2O. All analysis utilized raw outflow numbers
derived from the linear regression equations.
Resistance At steady-state pressure, ventricular inflow
rate equals CSF outflow rate. From the regression ana-
lysis of steady-state ICP versus flow, the CSF outflow
resistance can be calculated from the slope of the line.
All analysis utilized slopes derived from the linear re-
gression equations.
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The data was analyzed using repeated measures ANOVA,
post-hoc Dunnett’s, Students paired t-test and Pearson
Correlation test. Results were deemed statistically signifi-
cant at p≤ 0.05.
Results
Intranasal administration of drug shifts intracranial
pressure versus cerebrospinal fluid curves to the right
Given the direct connection between the CSF compart-
ment and the extracranial lymphatics within the nasal
turbinate region, we hypothesized that the nebulization
of pharmacological agents into the nasal cavity may in-
crease CSF absorption (Figure 1). While the delivery of
saline (n = 5) did not alter CSF absorption, we observed
that the delivery of agents such as noradrenaline
(NA, n = 5), L-NMMA (n = 4) and U46619 (n = 5) at steady
state intracranial pressures increased CSF absorption in a
dose dependent manner relative to no drug treatment. This






























































Figure 4 Increasing drug dose resulted in a significant increase in CS
specific drug effects at a steady-state pressure of 45 cmH2O, we plotte
(A) saline delivery, (B) noradrenaline (NA) at 50 μM and 500 μM (n = 5), (C) L
(n = 5) and (E) U46619 at 1 mM, 25 cmH2O (n = 3). Asterisk denotes significaICP relative to no drug treatment at a specific outflow rate
(Figure 2A to E).
CSF absorption is dependent on drug concentration
To address how ICP influences CSF absorption, outflow
rates were calculated using regression analysis. The ability
of a pharmacological agent to alter CSF absorption was re-
lated to the steady-state ICP, and the concentration and
class of pharmacological agent delivered. Normal ICP in
adult humans is approximately 10 cmH2O. In contrast,
traumatic brain injury or intracranial hemorrhage have
been found to result in ICP reaching above 40 cmH2O,
and aggressive interventions are typically initiated when
pressures exceed 30 cmH2O [19-21]. To mirror ICP ranges
typically found in severe clinical cases, we therefore calcu-
lated CSF outflow rates using linear regression with a
steady state pressure of 25 cmH2O and also by extrapola-
tion of the data, at 45 cmH2O. At a steady state pressure of
25 cmH2O there was no statistically significant drug effect













































F outflow at 45 cmH2O ICP. In order to stratify the correlation of the
d drug concentrations against CSF outflow using extrapolated data.
-NMMA at 10 μM and 100 μM (n = 4), (D) U46619 at 0.1 μM and 1.0 μM



























Figure 5 Delivery of pharmacological agents alters CSF outflow
resistance. To address whether a correlation existed between an
overall drug effect and resistance, data points from all agents under
no drug treatment (NT), the delivery of the first set of agents (drug
conc.#1; 50 μM NA, 10 μM L-NMMA, 0.1 μM U46619) and the
delivery of the second set of agents (drug conc.#2; 500 μM NA,
100 μM L-NMMA, 1 μM U46619) were plotted against resistance to
outflow, which was derived from the linear regression analysis of the
raw data. The straight line linking the averages within each
treatment group was calculated with the Pearson correlation test.
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at a steady state pressure of 45 cmH2O, a strong cor-
relation was found between drug concentration and
CSF absorption (r = 0.42, p = 0.0058) (Figure 3B). In-
deed, the delivery of 100 μM L-NMMA significantly
increased CSF absorption by an average of 2.29 fold over
no treatment (2.29 ± 0.34 mL/min), while delivery of
1 μM U46619 resulted in an average increase of 2.44 fold
in CSF absorption over no treatment (2.44 ± 0.55 mL/min)
(Figure 4C and D). Similarly, at steady state pressures of
30 (see Additional file 1: Figure S1), 35 and 40 cmH2O
(data not shown), CSF outflow rates were increased
significantly relative to no treatment upon delivery of
100 μM L-NMMA and 1 μM U46619. Saline delivery
did not significantly increase CSF absorption (0.88 ±
0.097 mL/min) (Figure 4A). A positive trend of increased
CSF absorption with the delivery of NA was observed,
however it did not reach statistical significance at any
steady-state pressure (Figure 4B). Conversely, the delivery
of 1 mM U46619 at 25 cmH2O significantly decreased
CSF absorption by 0.71 fold (0.71 ± 0.0098 mL/min), likely
due to lymphatics becoming tonic at this concentration
(Figure 4E).
Pharmacological agents delivered intranasally change CSF
outflow resistance
Given that the observed total drug effect increased over-
all CSF absorption (Figure 3B) we hypothesized that this
would correlate with a decrease in CSF outflow resist-
ance under steady-state pressure. Indeed, we observed
that increasing drug concentrations correlated inversely
with outflow resistance across all drug classes (r = −0.26,
p = 0.046 one-way probability) (Figure 5).
Discussion
Expansion of the ventricular space due to a deficit in
CSF absorption can lead to an increase in ICP and a de-
crease in cerebral perfusion pressure, these scenarios
being commonly seen in traumatic brain injury and
hydrocephalus. With regards to the latter, the most com-
mon solution is either CSF diversion with a shunt or
endoscopic third ventriculostomy (ETV), both being
highly invasive with potential long-term negative conse-
quences. From a theoretical perspective, the intranasal
delivery route for pharmacological agents may provide
a means to modulate CSF outflow in a non-invasive
manner by targeting the lymphatic vasculature at the
cribriform plate. In this report we provide proof-of-
concept that supports the above hypothesis using well-
characterized albeit not necessarily clinically-applicable
pharmacological agents that modulate the lymphatic
vasculature resulting in a change in CSF outflow.
Our data highlights a number of important consider-
ations when modulating CSF absorption intranasally.Indeed, clear differences exist between certain classes of
agents in their ability to promote CSF absorption. For
example, NA appears to be less efficient in inducing
CSF absorption when compared to the thromboxaneA2
analogue U46619. Consistent with this observation, in vitro
experiments using isolated lymphatic vessels support our
in vivo analysis [22,23], and underscore the importance of
selecting and characterizing optimal concentrations and
dosing of pharmacological agents that will efficiently
modulate CSF absorption. Furthermore, the data suggests
that the attenuation of lymphatic pumping with the deliv-
ery of L-NMMA also results in an increase in flow and a
decrease in resistance. This may be related to a the-
oretical increase in vessel radius driven by the actions of
L-NMMA. Consistent with this, an increase in vessel
diameter was also observed in eNOS−/− mice as well as
after NOS inhibition in control mice [24]. Additionally,
in our model the efficacy of a drug appears pressure
dependent; the higher the pressure, the greater the drug
effect.
While our hypothesis focuses on modulating the tur-
binate lymphatic vasculature in order to influence CSF
absorption, other pathways may play a role in augment-
ing CSF outflow with the most obvious being the uptake
of drug into the blood vasculature. Indeed, it has been
demonstrated that the intravenous delivery of catechol-
amines can influence lymphatic contractile activity and
flow from efferent lymphatic vessels in sheep [10,25].
However, it is unclear whether the systemic circulation
of pharmacological agents can ultimately influence CSF
absorption via the turbinate lymphatics. Future studies
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how intranasal drug delivery influences CSF absorption.
Conclusions
We have demonstrated the utility of delivering pharma-
cological agents intranasally to modulate CSF absorption
non-invasively. This has the potential to complement
the current surgical interventions that are used to treat
pathologies characterized by a deficit in CSF absorp-
tion such as hydrocephalus. Indeed, procedures to treat
hydrocephalus such as ETV result in an increase in CSF
drainage from the ventricles into the subarachnoid space;
the augmentation of CSF absorption via the nasal lym-
phatics coupled with other interventions may aid in CSF
clearance.
Additional file
Additional file 1: Figure S1. Increasing drug dose results in a significant
increase in CSF outflow at 30 cmH2O ICP. At a constant ICP of 30 cmH2O,
drug concentrations were plotted against CSF outflow for (A) saline delivery,
(B) noradrenaline (NA) at 50 μM and 500 μM (n = 5), (C) L-NMMA at 10 μM
and 100 μM (n = 4) and (D) U46619 at 0.1 μM and 1.0 μM (n = 5). Asterisk
denotes significance relative to NT (ANOVA/Dunnett’s test).
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